Evidence map›Paper›PMID 28008602›Full record

ArticleFEBS letters2017

MicroRNA-335-5p and -3p synergize to inhibit estrogen receptor alpha expression and promote tamoxifen resistance.

Elizabeth C Martin, Adrienne K Conger, Thomas J Yan, Van T Hoang, David F B Miller, Aaron Buechlein, Douglas B Rusch, Kenneth P Nephew, Bridgette M Collins-Burow, Matthew E Burow

Abstract readLetter
PubMed Full text at PMC Publisher
In one paragraph

Article in FEBS letters, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 29 papers.

0numbers the graph read from it
0cells of the map it votes in
29citing papers in PubMed
2.4field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

29 citing papers in PubMed, 47 citations in OpenAlex.

  1. Review
  2. The Role of Heavy Metals in the Biology of Female Cancers.International journal of molecular sciences · 2025
    Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Review
  12. Article
  13. Review
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 6 institutions in 1 country.

Elizabeth C MartinDepartment of Biological and Agricultural Engineering, Louisiana State University and LSU Agricultural Center, Baton Rouge, LA, USA.
Adrienne K CongerDepartment of Medicine, Vanderbilt University Medical Center, Nashville, TN, USA.
Thomas J YanDepartment of Medicine-Section of Hematology and Medical Oncology, Tulane University, New Orleans, LA, USA.
Van T HoangDepartment of Medicine-Section of Hematology and Medical Oncology, Tulane University, New Orleans, LA, USA.
David F B MillerMedical Sciences and Department of Cellular and Integrative Physiology, Indiana University School of Medicine, Bloomington, IN, USA.
Aaron BuechleinIndiana University Center for Genomics and Bioinformatics, Bloomington, IN, USA.
Douglas B RuschIndiana University Center for Genomics and Bioinformatics, Bloomington, IN, USA.
Kenneth P NephewMedical Sciences and Department of Cellular and Integrative Physiology, Indiana University School of Medicine, Bloomington, IN, USA.
Bridgette M Collins-BurowDepartment of Medicine-Section of Hematology and Medical Oncology, Tulane University, New Orleans, LA, USA.
Matthew E BurowDepartment of Medicine-Section of Hematology and Medical Oncology, Tulane University, New Orleans, LA, USA.
Indiana University Bloomington · USIndiana University School of MedicineTulane Medical Center · USTulane University · USLouisiana State University Agricultural Center · USVanderbilt University Medical Center · US

Funding

Tracking & Evaluation CoreU54GM104940 · NIGMS · LSU PENNINGTON BIOMEDICAL RESEARCH CTR · PI Peter Todd Katzmarzyk · 2012 to 2026
$69.1M
UNCOVERING THE MECHANISMS OF OSTEOSARCOMA METASTASIS SUPPRESSION BY MTBPP20RR020152 · NCRR · TULANE UNIVERSITY OF LOUISIANA · PI YOU, ZONGBING · 2004 to 2011
$17.0M
Predicting Drug Resistance in Cancer Genomes by DMA Methylation ProfilingU54CA113001 · NCI · UNIVERSITY OF TEXAS HLTH SCIENCE CENTER · PI HUANG, TIM H.-M. · 2004 to 2014
$16.1M
Kinase mediated suppression of metastasis in breast cancerR01CA174785 · NCI · TULANE UNIVERSITY OF LOUISIANA · PI COLLINS-BUROW, BRIDGETTE MICHELLE · 2016 to 2020
$1.8M
MEK5-Erk5 in breast cancer resistanceR01CA125806 · NCI · TULANE UNIVERSITY OF LOUISIANA · PI BUROW, MATTHEW E. · 2010 to 2014
$1.5M
NCI NIH HHS R01 CA125806NCI NIH HHS R01 CA174785NCI NIH HHS U54 CA113001NCRR NIH HHS P20 RR020152NIGMS NIH HHS U54 GM104940NIMHD NIH HHS L60 MD005539
6 · The paper itself

Abstract

microRNAs (miRNAs) are small noncoding RNA molecules involved in the regulation of gene expression and play critical roles in human malignancies. Next-generation sequencing analysis of the MCF-7 breast cancer cell line overexpressing miR-335-5p and miR-335-3p demonstrated that the miRNA duplex repressed genes involved in the ERα signaling pathway, and enhanced resistance of MCF-7 cells to the growth inhibitory effects of tamoxifen. These data suggest that despite its conventional role in tumor suppression, the miR-335 transcript can also play an oncogenic role in promoting agonistic estrogen signaling in a cancerous setting.

Indexed as

Breast NeoplasmsDrug Resistance, NeoplasmEstrogen Receptor alphaFemaleGene Expression Regulation, NeoplasticHigh-Throughput Nucleotide SequencingHumansMAP Kinase Signaling SystemMCF-7 CellsMicroRNAsRNA, MessengerTamoxifenESR1 protein, humanEstrogen Receptor alphaMicroRNAsMIRN335 microRNA, humanRNA, MessengerTamoxifenbreast cancerendocrine resistanceestrogen receptorisoformmicroRNAmiRNA-335

Identifiers

PMID28008602
PMCPMC5853108
OpenAlexW2566955250

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.